Literature DB >> 686900

Medullary thyroid carcinoma: relationship of method of diagnosis to pathologic staging.

S A Wells, S B Baylin, D S Gann, R E Farrell, W G Dilley, S H Preissig, W M Linehan, C W Cooper.   

Abstract

Medullary thyroid carcinoma (MTC) develops in virtually all patients affected with multiple endocrine neoplasia type II (MEN II), a disease inherited as an autosomal dominant trait. The thyroid tumor cells secrete calcitonin (CT) and the detection of elevated plasma levels (>300 pg/ml) of this hormone in MEN II kindred members strongly suggests the presence of MTC even though it may not be evident clinically. Intravenously administered calcium ion (Ca(++)) and pentagastrin (Pg) are potent CT secretagogues which are of particular value in establishing the early diagnosis of MTC. In evaluating seven kindreds with MEN II, we detected 90 patients with MTC. Depending on the method of diagnosis, they could be divided into three categories: Group 1; patients with no clinical evidence of MTC whose undetectable basal plasma calcitonin levels became elevated following intravenous Ca(++) or Pg, Group II; patients with no clinical evidence of MTC who had elevated basal plasma CT levels, and Group III; patients with clinically evident MTC. At the time of diagnosis of MTC, the patients in Group I were younger (20.5 +/- 1.9 years) than the patients in Group II (32.5 +/- 4.7 years, p < 0.005) and Group III (34.3 +/- 2.0, p < 0.00005). The incidence of residual MTC, as indicated by an elevated plasma CT level following provocative testing postoperatively, was less frequent in patients diagnosed biochemically ([6/34]; Group I, 4/26 and Group II, 2/8) than in those diagnosed clinically (Group III, 15/26, p < 0.002). Furthermore, regional nodes were involved less often in patients diagnosed biochemically ([5/28]; Group I, 2/22 and Group II, 3/6) than in those diagnosed clinically (Group III, 15/24, p < 0.02). Distant metastases were only evident in Group III patients. Patients with MEN II who had the diagnosis of MTC established biochemically rather than clinically, had a more favorable pathological stage of disease at the time of thyroidectomy. This was especially true if the biochemical diagnosis had been by provocative testing.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 686900      PMCID: PMC1396960          DOI: 10.1097/00000658-197809000-00013

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  7 in total

1.  A radioimmunoassay for human calcitonin M.

Authors:  M B Clark; G W Boyd; P G Byfield; G V Foster
Journal:  Lancet       Date:  1969-07-12       Impact factor: 79.321

2.  A comparison of pentagastrin injection and calcium infusion as provocative agents for the detection of medullary carcinoma of the thyroid.

Authors:  J F Hennessy; S A Wells; D A Ontjes; C W Cooper
Journal:  J Clin Endocrinol Metab       Date:  1974-09       Impact factor: 5.958

3.  A short calcium infusion in the diagnosis of medullary thyroid carcinoma.

Authors:  J G Parthemore; D Bronzert; G Roberts; L J Deftos
Journal:  J Clin Endocrinol Metab       Date:  1974-07       Impact factor: 5.958

4.  Sipple's syndrome: medullary thyroid carcinoma, pheochromocytoma, and parathyroid disease. Studies in a large family. NIH conference.

Authors:  H R Keiser; M A Beaven; J Doppman; S Wells; L M Buja
Journal:  Ann Intern Med       Date:  1973-04       Impact factor: 25.391

5.  Comparison of serum calcitonin levels after a 1-minute calcium injection and after pentagastrin injection in the diagnosis of medullary thyroid carcinoma.

Authors:  R K Rude; F R Singer
Journal:  J Clin Endocrinol Metab       Date:  1977-05       Impact factor: 5.958

6.  Stimulation of thyrocalcitonin secretion by ethanol in patients with medullary thyroid carcinoma--an effect apparently not mediated by gastrin.

Authors:  S A Wells; C W Cooper; D A Ontjes
Journal:  Metabolism       Date:  1975-11       Impact factor: 8.694

7.  The early diagnosis of medullary carcinoma of the thyroid gland in patients with multiple endocrine neoplasia type II.

Authors:  S A Wells; D A Ontjes; C W Cooper; J F Hennessy; G J Ellis; H T McPherson; D C Sabiston
Journal:  Ann Surg       Date:  1975-10       Impact factor: 12.969

  7 in total
  21 in total

1.  99mTc(V)-dimercaptosuccinic acid scintigraphy for medullary thyroid carcinoma.

Authors:  A Miyauchi; K Endo; H Ohta; K Torizuka; F Matsuzuka; A Kobayashi; K Kuma; M Maeda
Journal:  World J Surg       Date:  1986-08       Impact factor: 3.352

Review 2.  Multiple endocrine neoplasia.

Authors:  R A Decker; S A Wells
Journal:  Jpn J Surg       Date:  1989-11

3.  Medullary thyroid carcinoma in Northern Ireland, 1967-1997.

Authors:  S J Dolan; C F Russell
Journal:  Ann R Coll Surg Engl       Date:  2000-05       Impact factor: 1.891

4.  Evaluation of surgical results and prediction of prognosis in patients with medullary thyroid carcinoma by analysis of serum calcitonin levels.

Authors:  A Miyauchi; F Matsuzuka; K Kuma; S Takai; K Nakamoto; K Nakamura; S Nanjo; M Maeda
Journal:  World J Surg       Date:  1988-10       Impact factor: 3.352

5.  Prevalence of C-cell hyperplasia and medullary thyroid carcinoma in a consecutive series of pheochromocytoma patients.

Authors:  S Jansson; G Hansson; H Salander; G Stenström; L E Tisell
Journal:  World J Surg       Date:  1984-08       Impact factor: 3.352

6.  Unilateral versus bilateral adrenalectomy in multiple endocrine neoplasia IIA.

Authors:  S Tibblin; J F Dymling; S Ingemansson; M Telenius-Berg
Journal:  World J Surg       Date:  1983-03       Impact factor: 3.352

7.  The surgical management of medullary thyroid carcinoma.

Authors:  C F Russell; J A Van Heerden; G W Sizemore; A J Edis; W F Taylor; W H ReMine; J A Carney
Journal:  Ann Surg       Date:  1983-01       Impact factor: 12.969

8.  The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report.

Authors:  Tomasz Gawlik; Andrea d'Amico; Sylwia Szpak-Ulczok; Aleksander Skoczylas; Elżbieta Gubała; Anna Chorąży; Kamil Gorczewski; Jan Włoch; Barbara Jarząb
Journal:  Thyroid Res       Date:  2010-11-03

9.  Monoclonal antibody detection of a circulating tumor-associated antigen. II. A longitudinal evaluation of patients with colorectal cancer.

Authors:  H F Sears; M Herlyn; B Del Villano; Z Steplewski; H Koprowski
Journal:  J Clin Immunol       Date:  1982-04       Impact factor: 8.317

10.  Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma.

Authors:  A Miyauchi; T Onishi; S Morimoto; S Takai; F Matsuzuka; K Kuma; M Maeda; Y Kumahara
Journal:  Ann Surg       Date:  1984-04       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.